About Gossamer Bio
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Founders and CEO: Faheem Hasnain
Founder and COO: Sheila Gujrathi, M.D
39 articles with Gossamer Bio
Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2 at 7:45 a.m. ET.
Gossamer Bio, Inc. announced Otello Stampacchia, Ph.D., of Omega Funds, resigned from the company’s Board of Directors.
Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types
Gossamer Bio to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, August 8, 2019, to discuss the Company’s financial results and provide a corporate update.
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Five Prime Therapeutics, Inc. announced the departure of Dr. Sheila Gujrathi from the company’s board of directors.
Gossamer Bio, Inc. announced its financial results for the quarter ended March 31, 2019 and provided a corporate update.
Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019
Gossamer Bio, Inc. announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.
Gossamer Bio, Inc. announced it entered into a five-year senior debt facility led by MidCap Financial.
Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14 at 1:00 p.m. PT.
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments.
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the following upcoming investor conferences:
Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gossamer Bio, Inc. announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share.
Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.
Gossamer Bio, Inc. announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of $16.00 per share.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.